Trial Synopsis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Trial synopsis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Trial Synopsis Today - Breaking & Trending Today
BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the bemcentinib arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated with standard of care alone); in BGBC020 it was 2 vs 3 respectively More detailed top line data expected to report in May ....
Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the bemcentinib arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated with standard of care alone); in BGBC020 it was 2 vs 3 respectively More detailed top line data expected to report in May BERGEN, Norway, April 19, 2021 /PRNewswire/ BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update from the Phase II clinical study evaluating the efficacy and safety of bemcentinib in hospitalised COVID-19 patients (BGBC020). ....
BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at. ....
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients [6], as compared to placebo (FAS). - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS). ....